Travere Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDTravere Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 92), indicating clear outperformance against the broad market. Earnings growth of 15% provides fundamental context to the price action. However, price is extended 28% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $40.44 | +5.50% | ABOVE |
| 50 SMA | $33.42 | +27.66% | ABOVE |
| 100 SMA | $32.96 | +29.44% | ABOVE |
| 150 SMA | $32.51 | +31.20% | ABOVE |
| 200 SMA | $29.34 | +45.42% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TVTX in an uptrend right now?
TVTX has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, TVTX is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is TVTX overbought or oversold?
TVTX's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is TVTX outperforming the market?
TVTX has a Relative Strength (RS) Rating of 92 out of 99. Yes, TVTX is a market leader, outperforming 92% of all stocks over the past 12 months.
Where is TVTX in its 52-week range?
TVTX is trading at $42.66, which is 88% of its 52-week high ($48.52) and 83% above its 52-week low ($13.88).
How volatile is TVTX?
TVTX has a Beta of 1.81 and 52-week volatility of 75%. It's more volatile than the S&P 500 - expect bigger swings.